Comparative Pharmacology
Head-to-head clinical analysis: MAZANOR versus MERIDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAZANOR versus MERIDIA.
MAZANOR vs MERIDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mazanor (mazindol) is a sympathomimetic amine that acts as an anorectic agent. It likely reduces appetite by increasing norepinephrine and dopamine levels in the hypothalamic feeding centers via reuptake inhibition and possibly by blocking serotonin receptors.
Sibutramine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that inhibits the reuptake of serotonin and norepinephrine in the hypothalamus, enhancing satiety and increasing energy expenditure.
1 mg orally once daily, titrated based on response and tolerability up to 2 mg once daily.
10–15 mg orally once daily, titrated to 15 mg maximum after 4 weeks if inadequate weight loss.
None Documented
None Documented
Terminal half-life is 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours).
Sibutramine: 1.1 hours; active metabolites M1 and M2: 14-16 hours (terminal half-life). Steady-state achieved within 4 days.
Primarily renal (85-90% as unchanged drug), with minor biliary/fecal elimination (5-10%).
Primarily hepatic (CYP3A4 metabolism) with renal excretion of metabolites; ~80% of dose excreted in urine (mainly as M1 and M2 metabolites) and ~10% in feces.
Category C
Category C
Appetite Suppressant
Appetite Suppressant